ライフサイエンスコーパス: waiting list

1 , yet a lack of organs means many die on the waiting list.

2 rease, if not eliminate, the pediatric liver waiting list.

3 donors with ESRD never gained access to the waiting list.

4 competing risks of death or removal from the waiting list.

5 omorbidity score at the time of entering the waiting list.

6 their patients about likely outcomes on the waiting list.

7 and 1 month following cessation of treatment/waiting list.

8 lantation >/=3 years after activation to the waiting list.

9 y is even greater for those remaining on the waiting list.

10 randomly assigned to a training program or a waiting list.

11 rom ECMO, and 2 patients died on ECMO on the waiting list.

12 ival was worse for patients remaining on the waiting list.

13 ith end-stage lung disease on the transplant waiting list.

14 n associated with increased mortality on the waiting list.

15 4-1.00) less likely to place patients on the waiting list.

16 s following the inclusion of patients on the waiting list.

17 the comparison group were put on a 12 month waiting list.

18 a transplant and patients who remain on the waiting list.

19 inactive (status 7) on the kidney transplant waiting list.

20 ess cumulative 1-year mortality while on the waiting list.

21 ship-related differences in placement on the waiting list.

22 s, who constitute more than 40% of the organ waiting list.

23 recipient with the highest MELD score in the waiting list.

24 ant or registration on the kidney transplant waiting list.

25 st be weighed against harms to others on the waiting list.

26 ved a retransplants, and 857 remained on the waiting list.

27 idney transplantation when compared with the waiting list.

28 nt matching and significant mortality on the waiting list.

29 ion scores for individuals on the transplant waiting list.

30 ansplant and from 8% to 76% for those on the waiting list.

31 y managed candidates on the heart transplant waiting list.

32 tervention with 15 matched controls from our waiting list.

33 and private facilities as per the transplant waiting list.

34 nts become seriously ill or die while on the waiting list.

35 men were placed on the renal transplantation waiting list.

36 losed by having the last donor donate to the waiting list.

37 aft for HCC and non-HCC patients on a common waiting list.

38 on the deceased-donor renal transplantation waiting list.

39 sequence may be an increase in deaths on the waiting list.

40 te of the mortality risk for patients on the waiting list.

41 while waiting or have been removed from the waiting list.

42 rst kidney transplant were identified on our waiting list.

43 ion scores for individuals on the transplant waiting list.

44 ival after dropout from the liver transplant waiting list.

45 hly effective in preventing mortality on the waiting list.

46 0 older children die on the liver transplant waiting list.

47 urrently receive the highest priority on the waiting list.

48 from the first point of active status on the waiting list.

49 duction of the activity resulting in doubled waiting-list.

50 th care systems with limited budgets or long waiting lists.

51 s; many patients deteriorate or die while on waiting lists.

52 istration than did those who remained on the waiting list (0.79, 95% CI 0.70-0.91).

53 ysical function worsened per 3 months on the waiting list: -0.38 kg in grip strength, -0.05 meters/se

54 0 years old on dialysis and placed on the KT waiting list, 1084 received a first KT from a deceased d

55 come vs nonprofit facilities (deceased donor waiting list: -13.2% [95% CI, -13.4% to -13.0%]; receipt

56 nts (8.2%) were placed on the deceased donor waiting list, 23 762 (1.6%) received a living donor kidn

57 Of 2181 patients registered on the waiting list, 802 (37%) died or were removed from the li

58 We sought to compare liver transplant waiting list access by demographics and geography relati

59 ocess, including access to a transplantation waiting list, access to transplantation once waitlisted,

60 ient survival compared with remaining on the waiting list (adjusted hazard ratio: 0.58; 95% confidenc

61 significant comorbidities, activated on the waiting list after 2007, or unsensitized at activation.

62 derwent lung transplant, and two died on the waiting list after 9 and 63 days on ECMO, respectively.

63 here are 216 patients on the lung transplant waiting list and 17 on heart and lung transplant list.

64 ansplant, 5669 (60%) died (2644 while on the waiting list and 3025 after being delisted).

65 4% of the study population was placed on the waiting list and 32.5% received a deceased donor transpl

66 cluded 9,043 patients on the lung transplant waiting list and 6,110 lung transplant recipients betwee

67 he life course of patients on the transplant waiting list and after LT.

68 Early addition to a waiting list and aggressive multimodal therapy provide e

69 ts to take into account risk of death on the waiting list and chance of survival posttransplant.

70 icantly higher rate of mortality both on the waiting list and following transplantation.

71 on policy for all patients on the transplant waiting list and for those with a functioning graft.

72 at comparing 5-year mortality rates between waiting list and kidney transplantation patients with he

73 s infection and compared death rates between waiting list and kidney transplantation.

74 edian time between being placed on the HELTx waiting list and LTx was 3 days (interquartile range: 1-

75 on (LT) during adolescence, disparity on the waiting list and post-LT outcome for young adults compar

76 ), analytical parameters, time on transplant waiting list and post-transplant complications.

77 Waiting list and posttransplantation outcomes were evalu

78 growing percentage of the overall transplant waiting list and raise questions about the stewardship o

79 to improvement in IBS symptoms compared to a waiting list and that treatment gains were maintained ov

80 andidates and nonexception candidates on the waiting list and to assess if the exception system contr

81 We analyzed OPTN data that included waiting list and transplant characteristics, geographica

82 The gap between patients on transplant waiting lists and available donor organs is steadily inc

83 re still more rarely referred or accepted to waiting lists and, if enlisted, have less chances of act

84 Ten patients underwent ITx, 4 were on the waiting list, and 4 were unavailable for follow-up.

85 es over time in patients on kidney allograft waiting lists, and an apparent lack of research-based ev

86 ly sensitized renal transplant candidates on waiting lists, and the presence of donor-specific alloan

87 equently, waiting times and mortality on the waiting list are increasing dramatically.

88 Patients on organ transplant waiting lists are evaluated for preexisting alloimmunity

89 ctive potential for 3-month mortality on the waiting list (area under the curve [AUC], vWF-Ag = 0.739

90 age, 52 years; 26% women) on the transplant waiting list at 113 centers, 19 815 (68%) underwent hear

91 Fifty candidates have been added to the waiting list at 15 centers.

92 ored at that point, whereas 1876 were on the waiting list at any time.

93 ved a KT and were censored, 1876 were on the waiting list at any time.

94 One patient was taken off the waiting list because of severe deterioration.

95 Time spent on the waiting list before liver transplantation (LT) provides

96 the United Network for Organ Sharing (UNOS) waiting list between 1999 and 2011.

97 ents who dropped out of the liver transplant waiting list between 2000 and 2016 in a single, large ac

98 man, the access gap to the kidney transplant waiting list between Medicaid and private insurance decr

99 trol group) and controls who remained on the waiting list but did not receive a transplant (waiting-l

100 and 579 506 patients who were placed on the waiting list but did not undergo a transplant.

101 In comparison with patients on the waiting list but not transplanted, and with all patients

102 red, low-income adults, drawing names from a waiting list by lottery.

103 easons for removal from the liver transplant waiting list by Organ Procurement and Transplantation Ne

104 An increased risk of dropout on the waiting list can be expected, but with equivalent and sa

105 survival (ITTS) metric as the percentage of waiting list candidates surviving at least 1 year after

106 ed in 2009 to reduce pediatric deaths on the waiting list cannot yet be determined.

107 Yearly trends in waiting list characteristics and transplantation rates w

108 revealing an association between higher SMD, waiting list (comparator) (beta = -0.33 [95% CI, -0.55 t

109 tes with exceptions fared much better on the waiting list compared to those without exceptions in mea

110 a, female subjects had greater access to the waiting list compared with male subjects (acute: 0.428 v

111 e less likely to experience dropout from the waiting list compared with those aged 18 to 24 years (ad

112 ricans had significantly lower access to the waiting list compared with whites (acute: 0.201 versus 0

113 ither the EuroFIT intervention or a 12-month waiting list comparison group.

114 ate prolonged exposure treatment (N=36) or a waiting list condition (N=30) and underwent a second sca

115 ate prolonged exposure treatment (N=36) or a waiting list condition (N=30).

116 l-guided psychodynamic therapy (N=207), or a waiting list condition (N=79).

117 elated symptom reductions (compared with the waiting list condition) demonstrated 1) greater dorsal p

118 ion-focused supportive therapy, or a 14-week waiting list condition.

119 The number of candidates on the waiting list continues to increase each year, while orga

120 (n=109), PE (n=104), CBT/PE (n=106), or to a waiting list control group (n=103).

121 on and treatment with care-as-usual (CAU) or waiting-list control for depressive and/or anxiety disor

122 ts randomly assigned to a therapy group or a waiting-list control group scanning was performed before

123 d 169 BCSs to either Internet-based CBT or a waiting-list control group.

124 -up call to facilitate Web site use, or to a waiting-list control.

125 Two-centre randomised waiting list controlled trial with 46 adults with persis

126 Compared to mostly inactive (waiting list) controls, psychological interventions redu

127 ates (HCC 79.05% versus non-HCC 40.60%), and waiting list death rates (HCC 4.49% versus non-HCC 24.63

128 d but exceptions were highly correlated with waiting list death rates, transplantation rates, and MEL

129 r transplantation rates and lower numbers of waiting list deaths.

130 rience significant functional decline on the waiting list, despite modest wait time and low baseline

131 ingly, patients dying within 3 months on the waiting list displayed elevated levels of vWF-Ag (P < 0.

132 kinetics in patients on a kidney transplant waiting list do not appear to be related to the interval

133 survival, and risk factors for death, after waiting list dropout due to hepatocellular carcinoma (HC

134 caring responsibilities, adherence, time on waiting list, estimated survival and quality of life (QO

135 es for prioritizing children and time on the waiting list, favoring patients with high predicted post

136 plant recipients returning to the transplant waiting list following first graft failure.

137 bsequent mortality in patients on the active waiting list for a deceased donor SOT and recipients wit

138 there were more than 100,000 patients on the waiting list for a kidney transplant from a deceased don

139 patients who have been on the deceased-donor waiting list for a long time or those with a high calcul

140 pared it with the effect of remaining on the waiting list for a potential transplant from a donor wit

141 egistration of a transplant candidate on the waiting list for an organ and the date of the first tran

142 namic therapy were significantly superior to waiting list for both remission and response.

143 l patients (n = 866) newly registered on the waiting list for heart transplantation between January 2

144 Consecutive patients referred or on the waiting list for heart transplantation from March 2013 u

145 months; 86% of the patients allocated to the waiting list for high-intensity CBT started treatment by

146 reas-kidney after loss of pancreas function (waiting list for IAK [WLI]).

147 The waiting list for kidney transplantation is long.

148 h end-stage renal disease leads to a growing waiting list for kidney transplantation resulting from t

149 lymphocytes from patients on dialysis on the waiting list for kidney transplantation.

150 e Andalusian Registry who were placed on the waiting list for KT during the study period (1984-2012).

151 including a decline in patients added to the waiting list for liver transplantation for hepatitis C.

152 onal study with follow-up of patients on the waiting list for liver transplants who subsequently rece

153 tructive sleep apnea syndrome in patients in waiting list for LT, and LT has an important influence i

154 nutritional status of a NASH patient in the waiting list for LT?

155 ocedures in 160 transplant candidates on the waiting list for lung (n = 126) or heart (n = 34) transp

156 ficant number of patients who die while on a waiting list for lung transplantation (LTx) has led seve

157 ecutive patients with ILD referred or on the waiting list for lung transplantation from May 2013 to D

158 ) greater than 50% and on the deceased-donor waiting list for more than 5 years to investigate the ef

159 rogate marker for risk stratification on the waiting list for OLT.

160 -organ damage resulting in registration on a waiting list for or receiving a solid organ transplantat

161 pients (OTRs); however, most patients on the waiting list for organ transplant in the United States a

162 y kidney transplant candidates placed on the waiting list for primary listing from 2001 to 2015.

163 e criteria to accept elderly patients on the waiting list for RT?

164 the medical-therapy group were assigned to a waiting list for surgery.

165 se in male renal patients on the transplant waiting list for their first kidney graft, using sensiti

166 All patients were on a waiting list for therapist-led CBT (treatment as usual).

167 heart transplantation and in patients on the waiting list for these organs.

168 During the last 20 years, waiting lists for renal transplantation (RT) have grown

169 the supportive therapy group, and 7% of the waiting list group had recovered from PTSD.

170 p and at baseline and 4 months later for the waiting list group.

171 Compared with the waiting-list group, greater improvement was observed in

172 randomly assigned to the intervention or the waiting-list group.

173 rates in the CBT, psychodynamic therapy, and waiting list groups were 36%, 26%, and 9%, respectively.

174 to verum acupuncture, sham acupuncture, and waiting list groups.

175 n organ donors and patients on the recipient waiting list grows, residents of the United States who a

176 enters active on the national deceased-donor waiting list had antibody titers (total immunoglobulin l

177 Unfortunately, the kidney transplant waiting list has ballooned to over 100,000 Americans.

178 d 0-11 years) candidates added yearly to the waiting list has declined.

179 of new candidates on the pancreas transplant waiting list has decreased steadily since 2000; only 100

180 market and transplant tourism exist, and the waiting list has not been eliminated.

181 ew and prevalent pediatric candidates on the waiting list have decreased.

182 tality and morbidity on the heart transplant waiting list have decreased.

183 onprofit dialysis facilities: deceased donor waiting list (hazard ratio [HR], 0.36 [95% CI, 0.35 to 0

184 Unfortunately, many patients die on the waiting list hoping for a chance of survival.

185 number of adult candidates were added to the waiting list in a single year since 1998; donation and t

186 gnificantly higher incidence of death on the waiting list in LWTR than in SWTR (8.4% versus 1.6%, P <

187 f-help demonstrated modest benefits over the waiting list in reducing OCD symptoms (adjusted mean dif

188 n transplanted and patients remaining on the waiting list in the United Kingdom.

189 13,346 adults placed on the lung transplant waiting list in the United States between 2005 and 2011.

190 ability of liver transplant and death on the waiting list in the United States varies greatly by dona

191 inequity in access to renal transplantation waiting lists, in favor of men, has long since been demo

192 ive adult candidates on the heart transplant waiting list increased by 19.2%.

193 cal urgency status decreased and time on the waiting list increased in 2011.

194 caring responsibilities, and longer time on waiting list increased priority.

195 priorities for future outcome reporting were waiting list length (56%), the quality of hospital facil

196 ivariate analyses, adjusting for time on the waiting list, maintenance on immunosuppression after tra

197 -six (186 males) of 411 patients entered the waiting list (median age, 23 yr; range, 5-58 yr).

198 gitudinal trajectory of physical function on waiting list mortality (=death or delisted for being too

199 udinal trajectories of physical function and waiting list mortality adjusted for MELD-Na, albumin, he

200 nt candidates with minimal impact on overall waiting list mortality and posttransplant outcomes.

201 ring tertiles 2 and 3 with tertile 1, showed waiting list mortality hazard ratios of 1.62 (95% confid

202 higher-risk organs with the consequences on waiting list mortality if the donor pool is reduced furt

203 F and LAS were significantly associated with waiting list mortality in univariate analyses.

204 atients with irreversible liver disease, the waiting list mortality rate for children younger than 6

205 zation of available donor bowels and a lower waiting list mortality rate.

206 The risk for waiting list mortality varies considerably among HT cand

207 Waiting list mortality was not different across eras (14

208 model was developed to predict the risk for waiting list mortality within 90 days, and listed patien

209 generally increases with increasing risk for waiting list mortality, there is no measurable benefit i

210 ver transplantation and its association with waiting list mortality.

211 splantation (LT) exceeds supply, with rising waiting list mortality.

212 carcity of suitable donors resulting in high waiting list mortality.

213 to offer timely transplantation and decrease waiting list mortality.

214 , in candidates stratified by their risk for waiting list mortality.

215 n measure were significantly associated with waiting list mortality: grip (hazard ratio = 0.89, 95% c

216 significantly improved prediction of 3-month waiting-list mortality (AUC, MELD-Na-vWF = 0.804).

217 d to prioritize organ allocation to minimize waiting-list mortality and maximize 1-year survival.

218 This has created unacceptably high waiting-list mortality for lung transplant recipients.

219 p to prioritize organ allocation to decrease waiting-list mortality.

220 Among patients on the waiting list (n = 1876) who died (n = 446; 24%), 272 (61

221 d exposure therapy (n = 36) versus treatment waiting list (n = 30).

222 3 patients on the National Kidney Transplant Waiting List (NKTWL) are suspended from the list at leas

223 3 patients on the National Kidney Transplant Waiting List (NKTWL) is suspended from the list at least

224 being registered on the national transplant waiting list (odds ratio=0.69; 95% confidence interval,

225 on of kidneys from 2200 deceased donors to a waiting list of 5500 patients and produced estimates of

226 ublic education are necessary to address the waiting list of over 100,000 patients.

227 nts were well tolerated and were superior to waiting list on nearly all outcome measures; no differen

228 was observed between supportive therapy and waiting list on quality of life.

229 r-transplant control group and 89.6% for the waiting-list-only control group), 3 years (91.7% vs. 83.

230 iting list but did not receive a transplant (waiting-list-only control group).

231 r-transplant control group and 47.1% for the waiting-list-only control group; 76.3% for recipients wi

232 imary outcome was patient death while on the waiting list or after transplant.

233 (2007 for kidneys) who were removed from the waiting list or died awaiting a graft within 1 year was

234 verity scores did not correlate with time on waiting list or outcome.

235 re matched with controls who remained on the waiting list or received a transplant from a deceased do

236 o mortality for patients who remained on the waiting list or received DDLT (no LDLT group) according

237 he cumulative incidence of being placed on a waiting list or receiving a solid organ transplantation,

238 in 2006 to placement on the renal transplant waiting list or to December 31, 2009.

239 robability of being listed on the transplant waiting list or with a longer time from dialysis start u

240 CBT was compared with a control (usual care, waiting list, or attention control) in individuals with

241 on of maintenance dialysis, placement on the waiting list, or receipt of a living or deceased donor k

242 -cytometric cross-match versus 65.0% for the waiting-list-or-transplant control group and 47.1% for t

243 ol group at 1 year (95.0%, vs. 94.0% for the waiting-list-or-transplant control group and 89.6% for t

244 received a transplant from a deceased donor (waiting-list-or-transplant control group) and controls w

245 mporary continuous-flow LVADs have favorable waiting list outcomes; however, they worsen significantl

246 p when compared to those who remained on the waiting list (p < 0.0001).

247 nabling improved organ accessibility for the waiting list patients and a better prediction of antibod

248 also a marginally significant difference in waiting list placement by chain size: large chains compa

249 re enlistment; however, once included on the waiting list, priority strategies should be implemented

250 n in Oregon based on lottery drawings from a waiting list provided an opportunity to evaluate these e

251 on the deceased donor kidney transplantation waiting list, receipt of a living donor kidney transplan

252 The number of new waiting list registrations decreased, with the Northeast

253 tive smoking history donor, by analysing all waiting-list registrations during the same period with a

254 Nevertheless, mortality on the waiting list remains significantly higher than after tra

255 ith living donor transplantation, death, and waiting list removal as competing events.

256 The factors that increased the risk of waiting list removal due to death/deterioration were poo

257 More data on waiting list risk and outcomes should be provided.

258 lysis status, eGFR, time to transplantation, waiting list status, contrast material volume at index i

259 Alternate waiting list strategies expand listing criteria for pati

260 % decrease in estimated transplant candidate waiting list survival at a given center, there was an in

261 c (EXCOR) ventricular assist device improves waiting list survival for pediatric heart transplant can

262 t for patients with lower estimated expected waiting list survival without transplant (29% at high su

263 between survival after heart transplant and waiting list survival without transplant at 5 years.

264 ignificantly lower estimated expected 5-year waiting list survival without transplant.

265 Prediction of 3-month waiting-list survival was assessed by receiver operating

266 tation within 1 year after activation to the waiting list than with delayed non-ECD transplantation >

267 t transplanted, and with all patients on the waiting list, the risk of death after EGL decreased to b

268 lants was 124.6 per 100 patient-years on the waiting list; the highest rate was for patients aged les

269 in the number of patients on the transplant waiting list, there remains a significant gap between th

270 ent of disease stage IV lesions and a longer waiting list time and being older at the time of the tra

271 tients if they had undergone, or were on the waiting list to undergo, lung transplantation, lobectomy

272 ing from donation directly to deceased-donor waiting lists to benefit one recipient or chain transpla

273 er randomisation; surgeons coordinated their waiting lists to schedule surgeries as close as possible

274 bloc transplantation versus remaining on the waiting list using the sequential Cox approach.

275 oved as "too sick" to number who died on the waiting list varied by region from 0.23 to 0.94, indicat

276 e incidence of transplantation or being on a waiting list was 0.54% (95% CI 0.40-0.67) for kidney tra

277 Mortality on the waiting list was 18% in 2015, 4% of patients were delist

278 Overall mortality on the waiting list was 24%, and cardiovascular disease was the

279 ary outcome; placement on the deceased donor waiting list was also examined.

280 access to the national renal transplantation waiting list was assessed in 9497 men and 5386 women age

281 A major cause of death in the waiting list was cardiovascular diseases, whereas infect

282 ership) on placement on the renal transplant waiting list was evaluated by multi-level mixed-effect r

283 nal dysfunction on the liver transplant (LT) waiting list was obtained from Organ Procurement and Tra

284 27.29% of the waiting list was occupied by candidates with exceptions.

285 ipient's status on the heart transplantation waiting list was updated to reflect a willingness to acc

286 From the UK adult kidney transplant waiting list, we selected crossmatch positive living don

287 nd unacceptably high mortality on transplant waiting lists, we discuss different systems used interna

288 in 2011, 41% of prevalent candidates on the waiting list were aged 18 years or older.

289 Disparities in access to the waiting list were mitigated in Hispanic patients with pr

290 aracteristics, MELD-Na, and mortality on the waiting list were recorded.

291 live donor as compared with remaining on the waiting list, whether or not a kidney from a deceased do

292 uld substantially reduce the nation's kidney waiting list while providing many more donors the opport

293 dney disease patients on the transplantation waiting list who underwent renal transplantation.

294 antation (LT) are often treated while on the waiting list with locoregional therapy (LRT), which is a

295 The risk for death while on the waiting list within 90 days increased from 1.6% to 19% a

296 ver, seven lung) and 67 were registered on a waiting list without receiving a transplant (21 kidney,

297 quently either died or were removed from the waiting list without receiving a transplant.

298 0 years compared with those remaining on the waiting list (WL) according to their comorbidities.

299 and allocated to a patient on their elective waiting list (WL) based on unit prioritization.

300 55), including PE therapy, EMDR therapy, and waiting list (WL) of 13 outpatient mental health service